-
Evaluation of the implementation of coronary stent centralized procurement: the comments of medical institutions have become an important indicator
Time of Update: 2022-01-25
The notice mentioned that the assessment objects are the city's medical insurance designated medical institutions (referred to as "medical institutions") that participate in the centralized procurement of coronary stents organized by the state, excluding those who did not participate in the report in the first year but purchased, and newly participated in the following year.
-
Pilot varieties of medical insurance payment standards: 24 in Guizhou and 29 in Jiangxi...
Time of Update: 2022-01-25
The medical insurance payment standards for non-selected drugs under the same generic name for centralized procurement of drugs at the national or provincial level shall be formulated separately .
-
WHO: Existing new crown vaccines need to be updated to deal with future mutant strains
Time of Update: 2022-01-24
Specifically, the updated vaccine strain components need to be genetically and antigenically similar to the circulating mutant virus, be more effective in preventing infection, and elicit a "broad, strong and durable" immune response to "reduce the risk of Need for continuous reinforcement needles" .
-
It's 2022, why is the HPV vaccine so hard to grab?
Time of Update: 2022-01-23
Earlier data from the National Bureau of Statistics showed that about 120 million people of the appropriate age (16-26 years old) with the nine-valent HPV vaccine .
-
The new coronavirus keeps mutating, is vaccination still effective?
Time of Update: 2022-01-23
9 billion doses of the new coronavirus vaccine .
Vaccination is still an effective means to strengthen the prevention and control of the new crown pneumonia epidemic .
In the face of a constantly mutating virus, is our new coronavirus vaccine still effective?
-
The collection of Chinese patent medicines is here!
Time of Update: 2022-01-23
The person in charge of the Department of Medicine Price and Bidding and Purchasing of the National Medical Insurance Bureau said that in recent years, the state has strongly supported the development of traditional Chinese medicine.
-
"14th Five-Year" National Eye Health Plan (2021-2025)
Time of Update: 2022-01-23
Main goals According to the "Planning", during the "14th Five-Year Plan" period, focus on strengthening the construction of ophthalmic medical service system, capacity building, and talent team, continue to improve the quality control system of ophthalmic medical care, and promote the expansion and extension of high-quality ophthalmic medical resources .
-
Looking forward to the "opening" of dental implant collection, so that people can spend less money on dental implants
Time of Update: 2022-01-23
For the first time at the national level, the centralized procurement of dental implants is proposed, which is an important measure to meet people's expectations and respond to people's livelihood concerns .
-
Hanyu Pharmaceutical became the fourth company to review atosiban acetate injection
Time of Update: 2022-01-23
Prior to this, Yangzijiang Guangzhou Hairui Pharmaceutical's atosiban acetate injection was approved as a supplementary application, and it is the third company that has passed the evaluation of this product .
-
The centralized drug sales counter is another city!
Time of Update: 2022-01-23
In addition to Yuncheng, Shanxi, Zibo, Shandong has piloted the "national centralized drug purchase counter" in October last year to encourage pharmacies to sell centralized drugs.
-
Small pollen enters a price increase cycle, will the market go up or down?
Time of Update: 2022-01-23
Yulin market: As new products of small pollen enter the market one after another, the supply of goods is not as smooth as in the previous period, and the actual digestion stage is entered, and the market price has turned from rising to firm .
-
Traditional pharmacies may face major changes, and DTP pharmacies have good opportunities for development
Time of Update: 2022-01-23
In May 2021, the National Medical Insurance Administration and the National Health and Health Commission jointly issued the "Guiding Opinions on Establishing and Improving the "Dual Channel" Management Mechanism for National Medical Insurance Negotiated Drugs" (hereinafter referred to as the "Guiding Opinions"), which will include designated retail pharmacies in the negotiation of drug supply.
-
A large number of health care products will be forced to stop production!
Time of Update: 2022-01-23
On January 13, the State Administration for Market Regulation once again solicited opinions on the Catalogue of Health Functions Permitted by Health Foods to Claim Non-nutrient Supplements (2022 Edition) and supporting documents .
-
Another Chinese patent medicine centralized procurement alliance is coming!
Time of Update: 2022-01-23
Only if the minimum average daily cost or minimum price of the non-exclusive product A purchase order drops by ≥15%, it is possible to obtain 70% of the pre-purchased volume in the first year and obtain incremental use .
-
After the national harvest, the analysis of the changes in the market structure of diabetes drugs!
Time of Update: 2022-01-23
. In the third batch of metformin hydrochloride centralized procurement, eight companies including Chongqing Kerui, Beijing Jingfeng, Shanghai Xinyi Tianping, CSPC Ouyi, Penglai Nuokang, Shijiazhuang Yiling, Hebei Tiancheng and North China Pharmaceutical won the bid for metformin hydrochloride tablets.
-
30 newly listed drugs are quickly listed on the Internet through the "green channel"!
Time of Update: 2022-01-23
According to the data, it is expected that in 2021, the R&D investment of Hengrui, Qilu and CSPC will reach a new high, with a total of more than 10 billion yuan .
-
Pfizer has become a new generation of multinational "drug king" AstraZeneca's poor performance in the Chinese market
Time of Update: 2022-01-22
The first three quarters of the top 10 multinational pharmaceutical companies were all over US$25 billion, and Novartis, Johnson & Johnson, BMS, GSK, Sanofi, Merck and AstraZeneca ranked fourth to tenth .
-
The 2022 collection target has been released!
Time of Update: 2022-01-22
In the next step, it is necessary to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients .
-
Beite Pharmaceuticals is the first to submit a 4-class generic application for Dacomitinib, Pfizer's new products soared by 200%
Time of Update: 2022-01-22
Figure 1: The latest product status of Bite Pharmaceuticals Source: Pfizer’s dacomitinib tablets were officially approved for marketing in China in May 2019, and can be used as a single drug for epidermal growth factor receptor (EGFR) No.
Figure 2: Sales of Pfizer’s dacomitinib tablets in the retail market (unit: 100 million yuan) Source: Minet.
-
The list of hospital rebates was exposed, and the "hidden rules" of the industry were thoroughly investigated
Time of Update: 2022-01-22
Recently, Ai Fen, director of the emergency department of Wuhan Central Hospital, posted a number of pictures on Weibo, involving doctors, public officials, and social workers who received kickbacks from Aier Ophthalmology in several counties and cities in Jiangsu, ranging from a few hundred yuan to more than 2,000 yuan.
